Functional characterization of late outgrowth endothelial progenitor cells in patients with end-stage renal failure

Transplant International

Volumn 27, Issue 5, 2014, Pages 437-451

  Zhao, Jing ^a   Bolton, Eleanor M ^b   Randle, Lucy ^b   Bradley, John Andrew ^b   Lever, Andrew M L ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

chronic rejection; end stage renal failure; endothelial progenitor cells; integrin; mesenchymal stem cells; renal transplantation

Indexed keywords

INTEGRIN; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 16; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR; PROLACTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOKINE;

ADIPOCYTE; ADULT; ARTICLE; CELL ADHESION; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CELLULAR PARAMETERS; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE RENAL DISEASE; ENDOTHELIAL PROGENITOR CELL; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LATE OUTGROWTH ENDOTHELIAL PROGENITOR CELL; MALE; MESENCHYMAL STEM CELL; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANGIOGENESIS; CELL CULTURE; CELL MOTION; CHRONIC KIDNEY FAILURE; CYTOLOGY; GENETICS; PATHOLOGY; PHYSIOLOGY;

ADULT; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; INTEGRINS; KIDNEY FAILURE, CHRONIC; MALE; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84898794637     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12277     Document Type: Article

References (64)

1. Shirwan H,. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation 1999; 68: 715.
2. Krenning G, Dankers PY, Drouven JW, et al,. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol 2009; 296: F1314.
3. Choi J-H, Kim KL, Huh W, et al,. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004; 24: 1246.
4. Eizawa T, Murakami Y, Matsui K, et al,. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 2003; 19: 627.
5. Herbrig K, Pistrosch F, Oelschlaegel U, et al,. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 2004; 44: 840.
6. Herbrig K, Gebler K, Oelschlaegel U, et al,. Kidney transplantation substantially improves endothelial progenitor cell dysfunction in patients with end-stage renal disease. Am J Transplant 2006; 6: 2922.
7. de Groot K, Bahlmann FH, Bahlmann E, Menne J, Haller H, Fliser D,. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 2005; 79: 941.
8. Yoder MC, Mead LE, Prater D, et al,. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801.
9. Asahara T, Murohara T, Sullivan A, et al,. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964.
10. Hill JM, Zalos G, Halcox JP, et al,. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593.
11. Ingram DA, Mead LE, Tanaka H, et al,. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752.
12. Bahlmann FH, Speer T, Fliser D,. Endothelial progenitor cells in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 341.
13. Rehman J, Li J, Orschell CM, March KL,. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164.
14. Kalka C, Masuda H, Takahashi T, et al,. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97: 3422.
15. Assmus B, Schachinger V, Teupe C, et al,. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009.
16. Tateishi-Yuyama E, Matsubara H, Murohara T, et al,. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427.
17. Chade AR, Zhu X, Lavi R, et al,. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009; 119: 547.
18. Zhang SJ, Zhang H, Wei YJ, et al,. Adult endothelial progenitor cells from human peripheral blood maintain monocyte/macrophage function throughout in vitro culture. Cell Res 2006; 16: 577.
19. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP,. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71.
20. Ingram DA, Caplice NM, Yoder MC,. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005; 106: 1525.
21. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC,. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005; 105: 2783.
22. Zhao J, Bolton EM, Ormiston ML, Bradley JA, Morrell NW, Lever AM,. Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury. Transpl Int 2012; 25: 229.
23. Urbich C, Aicher A, Heeschen C, et al,. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733.
24. Westerweel PE, Hoefer IE, Blankestijn PJ, et al,. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 2007; 292: F1132.
25. Sester U, Sester M, Heine G, Kaul H, Girndt M, Kohler H,. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402.
26. Vasa M, Fichtlscherer S, Aicher A, et al,. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: e1.
27. Stroncek JD, Grant BS, Brown MA, Povsic TJ, Truskey GA, Reichert WM,. Comparison of endothelial cell phenotypic markers of late-outgrowth endothelial progenitor cells isolated from patients with coronary artery disease and healthy volunteers. Tissue Eng Part A 2009; 15: 3473.
28. Yoon CH, Hur J, Park KW, et al,. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112: 1618.
29. He T, Peterson TE, Katusic ZS,. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol 2005; 289: H968.
30. Zhang Y, Ingram DA, Murphy MP, et al,. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009; 296: H1675.
31. Dewerchin M, Carmeliet P,. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012; 2: 1.
32. Adini A, Kornaga T, Firoozbakht F, Benjamin LE,. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002; 62: 2749.
33. Fischer C, Jonckx B, Mazzone M, et al,. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463.
34. Schubert SY, Benarroch A, Ostvang J, Edelman ER,. Regulation of endothelial cell proliferation by primary monocytes. Arterioscler Thromb Vasc Biol 2008; 28: 97.
35. Voskuil M, van Royen N, Hoefer IE, et al,. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol 2003; 284: H1422.
36. Yang L, Guo XG, Du CQ, et al,. Interleukin-1 beta increases activity of human endothelial progenitor cells: involvement of PI3K-Akt signaling pathway. Inflammation 2012; 35: 1242.
37. Aicher A, Zeiher AM, Dimmeler S,. Mobilizing endothelial progenitor cells. Hypertension 2005; 45: 321.
38. Urbich C, Dimmeler S,. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343.
39. Pawlak K, Mysliwiec M, Pawlak D,. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine 2008; 43: 98.
40. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH,. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702.
41. Lemstrom KB, Krebs R, Nykanen AI, et al,. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105: 2524.
42. Doi K, Noiri E, Nakao A, Fujita T, Kobayashi S, Tokunaga K,. Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol 2006; 17: 823.
43. Asahara T, Takahashi T, Masuda H, et al,. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964.
44. Suga S, Kim YG, Joly A, et al,. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 2001; 60: 1297.
45. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD,. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425.
46. Center DM, Cruikshank W,. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 1982; 128: 2563.
47. Wang S, Diao H, Guan Q, et al,. Decreased renal ischemia-reperfusion injury by IL-16 inactivation. Kidney Int 2008; 73: 318.
48. Cruikshank WW, Greenstein JL, Theodore AC, Center DM,. Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J Immunol 1991; 146: 2928.
49. Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM,. IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 1996; 168: 100.
50. Kurschner C, Yuzaki M,. Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J Neurosci 1999; 19: 7770.
51. Bannert N, Vollhardt K, Asomuddinov B, et al,. PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J Biol Chem 2003; 278: 42190.
52. Solanilla A, Grosset C, Duchez P, et al,. Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. Br J Haematol 2003; 120: 782.
53. Hynes RO,. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11.
54. Chavakis E, Urbich C, Dimmeler S,. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008; 45: 514.
55. Niu G, Chen X,. Why integrin as a primary target for imaging and therapy. Theranostics 2011; 1: 30.
56. Jiang Y, Jahagirdar BN, Reinhardt RL, et al,. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41.
57. Sata M, Saiura A, Kunisato A, et al,. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403.
58. Ross R,. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801.
59. Hillebrands J-L, Klatter FA, van den Hurk BMH, Popa ER, Nieuwenhuis P, Rozing J,. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411.
60. Jie KE, Zaikova MA, Bergevoet MW, et al,. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1875.
61. Uccelli A, Pistoia V, Moretta L,. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007; 28: 219.
62. Bartholomew A, Sturgeon C, Siatskas M, et al,. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42.
63. Ryan JM, Barry F, Murphy JM, Mahon BP,. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353.
64. Hoogduijn MJ, Dor FJ,. Mesenchymal stem cells: are we ready for clinical application in transplantation and tissue regeneration? Front Immunol 2013; 4: 144.